Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Glycyrrhizin’s reputation started in traditional medicine, especially throughout Asia and the Middle East. Long before pharma codes and global quality standards, practitioners extracted sweet roots from licorice plants hoping to soothe coughs, inflammation, or digestive issues. Modern chemical isolation began in the eighteenth century in Europe, but the process didn’t resemble today’s tightly regulated production. Over decades, researchers unlocked its chemical structure, traced to glycyrrhetinic acid bound to two glucuronic acid molecules. Western pharmacopoeias started mentioning glycyrrhizin as clinical trials caught up to ancient wisdom. Seeing this ingredient listed in BP, EP, or USP signals a long journey of acceptance and international study, adapting cultural heritage into a pharmaceutical mainstay.
Pharma grade glycyrrhizin isn’t just a powdered extract; it represents a gold standard of purity, traceability, and compliance. All three pharmacopeia codes—BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia)—mean the product meets regulatory standards for medicinal or food supplement application. Consistency matters because cross-border drug manufacturing depends on ingredients behaving the same way during tablet or syrup production. Synthetic alternatives haven’t replaced the appeal of natural glycyrrhizin, which maintains its spot in antihistamines, expectorants, skin creams, and even tobacco alternatives. The broad reach grows stronger as more researchers include glycyrrhizin in anti-viral, anti-inflammatory, and anti-cancer investigations.
Glycyrrhizin presents as a white to yellowish powder, sometimes with a faint odor. This compound dissolves well in hot water and only moderately in ethanol. The chemical formula runs at C42H62O16, forming a glycoside structure with a triterpenoid backbone. Neutral pH matters for product stability. An average melting point registers above 200°C, offering robustness during most pharmaceutical production cycles. It tends to crystallize from solution—a factor makers watch closely to prevent downtime during bulk preparation. Quality controllers focus on solubility, moisture content, assay value (usually upwards of 98% for pharma-grade), and impurity thresholds. Simple as licorice root seems, the isolated glycyrrhizin marks a leap from the earthy taste of candy to the demanding protocols of GMP labs.
Every batch at pharma scale carries a certificate of analysis summarizing identity, purity, moisture content, heavy metals, and residual solvents. Labels state origin, grade, batch, expiration date, and manufacturer’s details, aligning with PIC/S and ICH guidelines. Pharma manufacturers accept nothing less, since unknowns in a labeled drum could compromise the entire chain. Specifications draw from harmonized monographs, with tests like HPLC for purity, GC for solvents, and precise limits on lead, arsenic, and microbial contamination. In my days consulting for herbal supplement companies, regulatory checks always centered on supply-chain transparency and meticulous documentation—errors here not only erode trust but also block export permits and recall insurance. Proper labeling saves headaches across continents.
Extraction often begins by macerating licorice root slices with water, followed by filtration, purification and precipitation using food-grade solvents. The filtrate passes through carbon columns to strip out colored fragments. Once the glycyrrhizin precipitates—sometimes using ethanol—it is washed, dried under vacuum, mechanically milled, and sieved. Pharma operations, unlike folk herbalists, introduce tight GMP controls, closed-system filtering to prevent airborne cross-contamination, and extensive in-process monitoring. Technicians track temperature, pressure, and flow rate to squeeze out every gram at intended purity. Years of handling bulk botanicals taught me that extraction variables—water source, harvest age, filter mesh—change the yield as much as downstream chemistry does.
While most end-users want unchanged glycyrrhizin, chemists sometimes hydrolyze it using mild acid or enzyme catalysts to yield glycyrrhetinic acid. This variant pops up in advanced topical creams and as a molecular probe for anti-viral property tests. Sulfation or methylation have helped studies aiming for less sweet, more bioavailable analogues. Every tweak, from an extra sulfate to a shifted glycoside, requires complete re-testing for pharmacokinetic change. PhD students often discover that even minor modifications can flip a molecule from type-A sweetener to bitter pharma star. Synthetic routes remain tricky and rarely eclipse the precision of botanical extraction for natural glycyrrhizin.
Common synonyms include glycyrrhizic acid, glycyrrhizinic acid, and monoammonium glycyrrhizinate. Some suppliers brand glycyrrhizin extracts under proprietary names when they market to cosmetic or health food manufacturers, usually touting purity or “natural” origins. In patents and clinical literature, the substance might appear as glycyrrhizinate or lithium glycyrrhizinate if formulated for solubility control. Ingredient statements on pharmaceuticals typically use the standardized pharmacopeial name. Many import/export customs platforms recognize all these terms for one underlying molecule, as customs brokers and regulatory authorities try to keep everything harmonized.
Production floors run with HEPA filters, clean-in-place systems, and chemical-resistant gear because pharma-grade glycyrrhizin demands the same level of hygiene used for mainstream active ingredients like paracetamol or metformin. Occupational exposure guidelines come from MSDS data and national safety regulations, focusing on dust inhalation, dermal exposure, and potential cross-contamination with food or non-pharma goods. Operators monitor spills and air quality, using fume hoods for open operations and dedicating rooms for allergenic botanicals. Supply chain audits always look for compliance not only with GMP, but also with local labor and waste treatment standards. For finished-dose manufacturers, strict cleaning, batch separation, and traceability standards must stop cross-lot contamination.
Broadly respected for expectorant and anti-inflammatory effects, glycyrrhizin extends beyond traditional cough syrups. Topicals integrate it to soothe eczema and psoriasis, and supplements list it for gut and liver claims. Regulatory agencies have limited high-dose use due to adverse reactions, particularly from potassium depletion or blood pressure rises. In Japan, doctors often prescribe glycyrrhizin as a hepatoprotective agent for chronic hepatitis. Food manufacturers, meanwhile, leverage its powerful sweetness—up to 50 times that of sucrose—as a sugar substitute in licorice confections or tobacco products. Even the skincare sector values its soothing profile for sensitive skin lines. Each domain has brought its own standards, from pharmacopoeial monographs to INCI registration for cosmetics.
Recent years brought glycyrrhizin into cancer research, targeting its role in tumor cell apoptosis and prevention of metastasis in animal studies. Scientists also explore it as a modulator of viral replication, drawing special attention for hepatitis B and C, and even as an inhibitor of the SARS coronavirus family. R&D teams have mapped various delivery mechanisms, from liposomal encapsulation to nanoparticle carriers, striving for peak bioavailability and targeted therapy. Major research hospitals fund trials for systemic lupus and other autoimmune disorders, seeing the compound as both an anti-inflammatory and an immune regulator. Each new discovery brings scrutiny from journal reviewers, funding agencies, and regulatory committees, who weigh theoretical breakthrough against reproducible, evidence-based outcomes.
Toxicologists emphasize a balanced view: glycyrrhizin’s beneficial properties require careful dosing. Prolonged high intake disrupts sodium-potassium balance, pushes blood pressure upward, and risks pseudoaldosteronism—a state causing headaches, water retention, and muscle weakness. Animal studies outline a clear threshold, with adverse effects only above sustained therapeutic levels. Regulatory limits in food and pharmaceuticals reflect these findings. Some individuals feel side effects at lower doses, highlighting the need for personalized medicine and consumer warnings. In my technical support role, most serious cases arose from patients using licorice-based teas or supplements without product labels or guidance—not from prescription-grade material monitored by clinicians. The science calls for responsible communication and ongoing post-market surveillance.
Ongoing advances in synthetic biology could enable microbial production of glycyrrhizin, offering an alternative to large-scale licorice cultivation. Analytical advances may yield even purer, more targeted forms, suited for next-generation drug formulations. Researchers are close to mapping its molecular targets with precision, promising smart-drug approaches in virology, dermatology, and oncology. Regulators and consumer groups want even more transparent traceability, lowering the risk of adulteration or mislabeling in the global supply chain. Macro trends such as plant-based wellness, dietary limitations, and personalized medicine add fresh momentum, building on the foundation laid by centuries of traditional use and decades of lab research. Glycyrrhizin’s story shows no signs of slowing—in labs, clinics, or daily consumer wellness.
Glycyrrhizin catches the attention of scientists and herbalists alike. This compound, pulled mostly from licorice root, has served many cultures for centuries. Its use in traditional medicine stretches across Asia, the Middle East, and Europe—people have chewed licorice for everything from sore throats to stomach troubles.
Pharma grade glycyrrhizin—marked BP, EP, or USP—stands for more than just purity. It points to the strict standards set by the British, European, and U.S. Pharmacopeias. Companies test each batch, looking for consistent chemical makeup and removing impurities to fit these guidelines. That level of care pays off across healthcare and manufacturing.
Research keeps shining a light on this molecule’s range of effects. Glycyrrhizin acts as an anti-inflammatory—blocking certain enzymes and calming down immune reactions. Some hospitals turn to it in hepatitis treatments, especially in Japan. Doctors there inject it to counter liver inflammation and show improved outcomes in some patients.
Its antiviral side matters as well. Glycyrrhizin interrupts some viruses before they get too comfortable inside human cells. Covid-19 put a magnifying glass on this ability, as researchers studied it for a possible role in blocking the virus’s entry. In a world bracing for new pandemics, having broad-spectrum antiviral agents can’t be overlooked.
Sweets without sugar often disappoint. Glycyrrhizin, though, packs up to 50 times the sweetness of table sugar, all while avoiding the blood sugar spikes that worry diabetics. Food scientists have turned to it as a flavoring agent, masking bitterness and improving taste across syrups, lozenges, and cough drops.
Its natural origin and lengthy track record have helped food regulators in many countries approve its use. Less artificial flavoring, and a nod to centuries-old remedies: that’s a win for people who like to keep their ingredient lists simple.
Not every gift from nature comes free of warnings. Too much glycyrrhizin leads to its own set of troubles—high blood pressure, low potassium, and heart issues can crop up. Doctors see cases of licorice overuse more often than you’d think, and the science is concrete on these risks.
Companies stick with pharma-grade for a reason. Clean, measured supplies help keep side effects in check, and regulations keep bad actors from slipping adulterated extracts onto the market. Educating both consumers and healthcare practitioners seems key. The more that gets explained about safe dosing and interactions, the fewer emergency room visits linked to hidden licorice in supplements and snacks.
People want both safety and results. Limiting dosages in consumer products, stepping up research, and keeping a close eye on labeling must stay front-of-mind for regulators. I’ve seen patients turn to traditional remedies without realizing drug interactions. Honest, detailed conversations between doctors, pharmacists, and patients help everyone get better outcomes.
Pharma-grade glycyrrhizin stands out as a tool that offers both roots in tradition and promise for modern science. From liver treatments to a better tasting cough syrup, it keeps earning its place on the shelf—if we stay sharp about how it’s used.
Glycyrrhizin, extracted mainly from licorice root, holds a trusted place in medicines that fight inflammation, soothe sore throats, and address digestive issues. Drug companies rely on strict standards to keep patients safe, especially with ingredients that end up in tablets, syrups, and creams. Pharma grade glycyrrhizin must pass the benchmarks set by major monographs—BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia). These authorities don’t just come up with rules for the sake of it. Their standards reflect deep review by scientists, regulators, and manufacturers, all working to make sure glycyrrhizin not only works as expected but also never carries unwanted risks.
Purity matters more than anything. Pharmaceutical batches of glycyrrhizin require a minimum purity of between 98% to 99%, confirmed using tests like HPLC (high-performance liquid chromatography). That level of purity means no question marks about how much active ingredient each patient receives, every single dose.
Water and Moisture Content must stay low, typically under 5%, to stop spoilage and keep the compound stable from the day it’s made to the day it’s used in production. Excess moisture can easily turn into a home for harmful microorganisms, and that’s not a risk anyone wants to take.
Heavy Metal Levels get checked with even greater scrutiny than most realize. Limits sit close to 10 parts per million for lead and under 20 ppm for other heavy metals. This standard ensures there’s no buildup of metals over time that could harm organs or the nervous system.
Microbial Quality cannot slip. Any serious player in this field tests for total aerobic microbial count and fungi. Any sign of pathogens like Escherichia coli or salmonella gets flagged, and such lots never make it near a patient. These tests are critical, especially with APIs sourced from plants which already come with environmental contamination risks.
Appearance and Odor matter for more than just presentation. Any pharmaceutical ingredient that looks off—discolored, with solid clumps, or a musty smell—suggests improper handling or storage. Glycyrrhizin for pharma use gets delivered as pale yellow to light brown crystals or powder, and the taste is unmistakably sweet.
Meeting pharmacopoeial specs isn’t just about ticking boxes to clear a regulator. Patients rely on consistent results. If purity drops, a medicine may underdose someone who counts on its power. Higher levels of metals or microbes could lead to side effects, sometimes more trouble than the original ailment. I’ve seen suppliers try to cut corners, hoping a shipment sneaks by. It always catches up, with recalls, regulatory investigations, or loss of trust.
The future of glycyrrhizin in modern medicine keeps relying on strong science, open data, and regular auditing. I see more laboratories sharing results and adopting block-chain backed traceability to prevent fraud or error. For manufacturers and buyers, there’s no shortcut: test every batch, invest in transparent supply chains, and respond fast to new research about potential impurities.
Rely only on suppliers who post certification and hand over batch documentation without hesitation. Insist on independent lab testing, not just what comes from the factory floor. Keep records tight, track every shipment, and never gamble with unknown sources. Lab teams should keep equipment up to date—HPLC, atomic absorption, and microbial counters. Modern pharma needs trust built on evidence, not empty claims or shortcuts.
Glycyrrhizin comes from licorice root, which people have used in traditional remedies for thousands of years. These roots always carried a reputation for soothing throats, calming inflammation, and taming coughs. Modern times don’t abandon the past entirely; pharmacists and researchers still see value in glycyrrhizin, especially as new research shows its antiviral and anti-inflammatory properties.
Pharmaceutical grade glycyrrhizin carries designations like BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia). Each of these agencies demands finished product batches that pass purity and quality benchmarks. Each batch needs tests for contaminants such as heavy metals, pesticides, and microbiological impurities. If one batch falls short, it won’t end up in a finished drug. These safeguards protect patients from the unknown risks of impurities.
Quality and purity standards address the risks that can sneak into herbal extracts. Even then, side effects tie more to how much someone takes and for how long. Glycyrrhizin in small therapeutic doses often causes few side effects. Once doses tick upward—especially with long-term use—the chance of elevated blood pressure rises. This happens because glycyrrhizin impacts potassium and sodium levels in the body. Heart rhythm changes and swelling appear for some people, particularly those with sensitive blood pressure or kidney function.
Real cases help stress the point. Scientists in Japan documented instances where chronic use of licorice extracts caused pseudoaldosteronism—a condition where sodium retention leads to swelling and hypertension. A 2019 review in the journal Frontiers in Pharmacology reinforced the link between high glycyrrhizin intake and these health risks. The takeaway is clear: pharmaceutical manufacturers set clear dosing limits to avoid these dangers.
Glycyrrhizin shows promising abilities against viruses like hepatitis and even influenza. Some lab studies show activity against SARS, further spurring interest during times of viral outbreaks. Doctors and scientists continue to debate whether these benefits outweigh possible risks. The body of evidence suggests the ingredient can be safe when processed to strict standards and used as directed. I’ve talked with several clinicians in hospital settings who monitor electrolyte levels when prescribing medications with licorice extract. Careful patient screening and education remain essential.
Safety depends on careful oversight. Ongoing training helps pharmacists spot potential interactions between glycyrrhizin and drugs such as corticosteroids, diuretics, or medications that affect heart rhythm. Electronic health records now flag medications with glycyrrhizin to avoid missed warnings. Companies sourcing glycyrrhizin for medicines pay close attention to traceability, responsible supplier certification, and up-to-date quality inspections.
Some suggest greater public messaging around risks for sensitive groups—those with heart disease, high blood pressure, or chronic kidney issues. Healthcare providers need up-to-date, practical advice that doesn’t hide behind technical jargon. Open communication helps patients and providers weigh risks and benefits.
Demand for herbal derived ingredients keeps rising, reflecting both consumer trust in traditional medicine and ongoing research into plant compounds. Pharmaceutical grade glycyrrhizin offers benefits backed by modern science, so long as production and use align with international standards, clinical guidance, and common sense.
Working with pharmaceutical ingredients like Glycyrrhizin BP, EP, USP grade leaves no margin for error in packaging and storage. A lax approach risks product degradation, legal trouble, or even patient harm. From my work in the pharmacy space, regulations exist for a reason. Medicines and their ingredients carry a responsibility to users far beyond the factory floor.
A lot rides on the packaging. Glycyrrhizin, extracted from licorice root, comes as either a fine powder or granules. Humidity doesn’t play nice with it—moisture turns it into a sticky mess, encouraging clumps or spoilage. Most responsible suppliers use moisture-barrier bags or drums. Polyethylene and laminated aluminum foils do more than just hold the powder; they block out light, dust, and oxygen. I remember collecting a package where the inner liner kept out even the pharmacy’s sharp chemical smells—clear evidence of how a good barrier keeps impurities at bay.
Having worked at a dispensary, I know the trouble that comes from unclear labeling. Glycyrrhizin pharma grade packaging must display batch number, manufacturing date, expiry, and traceability information. Good suppliers add tamper-evidence, whether it’s a seal or shrink band, so any accidental opening is obvious before it even reaches lab storage. This protects both the handler and the end patient—a safeguard that can’t simply be assumed or taken lightly.
Temperature matters. Glycyrrhizin needs storage well below 30°C, away from direct light and heat sources. Even ambient lights in storerooms can affect sensitive substances over time, and uncontrolled rooms invite wild temperature swings. Some smaller clinics try to use regular storerooms; in my experience, this shortcut often pays back with degraded product or deviation reports. Professional setups use well-calibrated thermostats and limit access to trained staff only.
Cross-contamination causes major headaches. Pharmaceutical-grade Glycyrrhizin shares warehouse space with other chemicals, so dedicated shelving, frequent cleaning, and double-bagging help lower the risk. At one distribution hub, I watched as workers carefully recorded each lot’s journey from arrival to dispatch, cleaning after each transfer. This level of vigilance keeps dangerous mix-ups off the table and addresses traceability at every step.
The rules from BP, EP, or USP aren’t mere suggestions. These agencies expect compliance down to minute details, and audits can come unannounced. I’ve watched quality assurance officers refuse shipments for non-compliance—whether it’s a label error or wrong packaging material. Documentation matches every package, certificate of analysis included, to simplify recalls or investigations if issues arise with end-use products.
Problems don’t always stem from lack of knowledge but from shortcuts. It helps to train warehouse teams regularly and invest in stability monitoring—simple electronic loggers can record heat or humidity, catching problems before they hit the batch. Sharing these audits and transparency records up the supply chain boosts everyone’s trust.
Safe packaging and storage of Glycyrrhizin isn’t about ticking boxes. It’s an active choice that needs care from every handler. Industry standards draw from years of hard lessons—in this world, it pays off to follow them to the letter, every single day.
Glycyrrhizin often jumps out on ingredient lists for medicines and supplements. It gets attention because it comes from licorice root and shows up in cough syrups, liver protectants, and a collection of herbal remedies. Companies selling to global markets refer to “BP,” “EP,” and “USP” to highlight alignment with British, European, and United States Pharmacopeias. That matters for more than just paperwork. Doctors, patients, and regulators expect these standards to be met every time.
The rules set by BP, EP, or USP go beyond purity numbers or basic testing. They cover exact identification, potency, contaminants, and even how to test and store the material. Each pharmacopeia may throw in different details: The EP can be strict about specific microbial tests, the USP lists set values for heavy metals, and the BP may call out unique testing procedures. I’ve seen production batches fail release because one country’s pharmacopeia wanted a residue tested with a method that another left out.
In practice, a pharma-grade material must reach these benchmarks: consistent appearance, well-defined content of glycyrrhizinic acid, tight moisture limits, freedom from impurities like glycyrrhetinic acid, and no unacceptable solvents or heavy metals. The batch’s certificate of analysis (CoA) gets read top to bottom by buyers and regulators, and labs keep samples locked away for years, ready for any retests.
Standards aren’t just targets—they’re checked with every lot. Some glycyrrhizin manufacturers publish big claims, but the proof comes from audit trails and import inspections. Recently, I worked with a QA team verifying Chinese-supplied glycyrrhizin for a client. The supplier’s CoA matched USP and EP specs, but a confirmatory lab in Europe found too-high arsenic levels in one batch. The shipment stopped at customs until a compliant replacement arrived.
International trade adds complexity. Regulators from one region sometimes accept pharmaceutical-grade glycyrrhizin titled “compliant with USP, BP, EP” only if supported by up-to-date laboratory results. Documentation gaps can trigger rejections or expensive additional analyses, stalling product launches. Real compliance means blending technical know-how with transparent paperwork.
Quality failures in glycyrrhizin reach beyond paperwork headaches. Contaminated or substandard raw materials can trigger adverse reactions, lead to product recalls, or erode trust that patients put in their medicines. In 2021, one major recall in the herbal supplement industry started with untested raw materials with excessive residual solvents, leading to a blitz of new supplier audits and regulatory warnings.
The risk sits not just with suppliers. Pharmaceutical companies, compounding pharmacies, and supplement formulators also bear consequences if what’s delivered doesn’t match pharmacopeial grade as promised. Diligence at every step gives nobody the excuse of “not knowing.” The manufacturing facility must run validated processes, suppliers should provide full transparency, and importing distributors need to keep samples for cross-checks. One missing link can undermine every guarantee about meeting BP, EP, or USP benchmarks.
Global players can lower compliance risks by prioritizing long-term supplier partnerships over bottom-dollar sourcing. Using certified labs for routine testing, not just spot checks, helps catch surprises. Sharing results openly down the supply chain fills the gaps that paper certifications might leave. Regulators can help by updating public monographs promptly and clarifying where regional differences actually matter.
Customers and patients deserve the peace of mind that comes with knowing the label “BP/EP/USP grade” actually means a medicine or supplement won’t surprise them with dangerous extras or weak potency. Honest, transparent compliance keeps everyone safer—and trust in the system intact.
Chengguan District, Lanzhou, Gansu, China
